Allos to complete merger with AMAG Pharmaceuticals Allos Therapeutics.

Towards the completion of their merger, pending stockholder authorization and satisfaction of the other circumstances to closing explained in Allos’ definitive proxy declaration filed with the SEC on September 15, 2011. On October 7, 2011, the publicly exchanged pharmaceutical company that got previously submitted a proposal to acquire Allos for $2.20 per share in share and cash delivered a letter to Allos withdrawing its revised proposal to acquire Allos. As a result, Allos is no providing details to longer, or engaging in discussions or negotiations with, that ongoing company with regards to the revised acquisition proposal or any other acquisition proposal.. Allos to complete merger with AMAG Pharmaceuticals Allos Therapeutics, Inc. today announced that it continues to work with AMAG Pharmaceuticals, Inc.Dr. Michna is board certified in anesthesia, pain management and palliative care medicine. Ahead of earning his medical degree, he trained as a pharmacist at Rutgers University and later on attended law college and practiced laws as a medical malpractice trial attorney. Dr. Michna is involved with clinical analysis and lectures nationally on the legal areas of pain management. He’s active in lots of national discomfort societies and is previous chairman of the Pain Care Coalition and former chair of the American Pain Society’s Public Plan Committee. The John and Emma Bonica Public Assistance Award will pay tribute to this couple for their leadership in the pain-treatment movement. It recognizes contributions by an individual or organization through general public education, public service or other automobiles to communicate information about pain.